Date: 2016-01-08
Type of information: Pipeline acquisition
Acquired company: bacteriophage assets from Novolytics (UK)
Acquiring company: Ampliphi Biosciences (USA - VA)
Amount: undisclosed
Terms: * On January 8, 2016, AmpliPhi Biosciences announced it has acquired key assets from UK-based Novolytics Ltd., including bacteriophage-related intellectual property, bacteriophage libraries, formulation and regulatory know-how as well as GLP toxicology data.
Details: AmpliPhi Biosciences is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi\'s product development programs target infections that are often resistant to existing antibiotic treatments. The company has already acquired Biocontrol of London, UK, in late 2010, and Special Phage Services, of Sydney, Australia, in late 2012. AmpliPhi maintains a research and development facility in Sydney, and, as a direct result of earlier relationships forged by Special Phage Services with Flinders and Adelaide Universities in South Australia.
Related:
